Beta-Trace Protein in Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Guillain-Barré Syndrome: Clinical Utilization and a New Insight Into Pathophysiological Mechanisms

    February 2025 in “ Journal of the Neurological Sciences ”
    Ivan Kmezic, Rasmus Gustafsson, Magnus J. Hansson, Rayomand Press
    TLDR Beta-trace protein may help diagnose and predict treatment response in certain nerve disorders.
    Beta-trace protein (BTP) in cerebrospinal fluid (CSF) and plasma shows promise as a biomarker for diagnosing chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). It may be more informative than albumin in certain patients with Guillain-Barré syndrome (GBS) and CIDP who exhibit normal or mildly elevated Q.alb levels. Additionally, BTP in CSF could potentially predict therapy response in CIDP patients, although further validation in larger studies is necessary.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results